Responsabilité
MiYOSMART n’est pas homologué dans tous les pays, États-Unis compris, pour le traitement de la myopie et actuellement, il n’est pas disponible dans tous les pays, États-Unis compris.
Indications de la source
1. Vorliegende Hoya-Daten. Harris Interactive: HOYA Vision Care Konzepttests, MiYOSMART Sun. 07/2022
2. Ho CL, Wu WF, Liou YM. Dose-Response Relationship of Outdoor Exposure and Myopia Indicators: A Systematic Review and Meta-Analysis of Various Research Methods. Int J Environ Res Public Health. 2019;16(14):2595.
3. Jonas JB, Ang M, Cho P, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci. 2021;62(5):6.
4. Myopie-Umfragedaten. November 2022. Präsentiert im Rahmen des WSPOS Symposiums: Comprehensive Update on Myopia Management. 19. – 20. November 2022. Verfügbar unter: http://forum.wspos.org/symposium-part-1-comprehensive-update-on-myopia-management-2 (Letzter Zugriff am: 20.02.2023)
5. Sunlight Exposure & Children’s Eyes Consensus Statement. 2016. Verfügbar unter: https://www.wspos.org/wspos-sunlight-exposure-childrens-eyes-consensus-statement/ (Letzter Zugriff am: 20.02.2023)
6. Prevent Blindness. Children’s Eyes are More Susceptible to Long-Term Damage from UV Rays. 2011. Verfügbar unter: https://preventblindness.org/childrens-eyes-are-susceptible-to-long-term-damage-from-uv-rays/(Letzter Zugriff am: 20.02.2023)
7. Artigas JM, Felipe A, Navea A, Fandiño A, Artigas C. Spectral transmission of the human crystalline lens in adult and elderly persons: color and total transmission of visible light. Invest Ophthalmol Vis Sci. 2012;53(7):4076-4084.
8. Jonas JB, Ang M, Cho P, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci. 2021;62(5):6.
9. Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group. Progressive addition lenses versus single-vision lenses for slowing progression of myopia in children with high accommodative lag and near esophoria. Invest Ophthalmol Vis Sci. 2011; 52:2749–57.
10. Li FF, Yam JC. Low-Concentration Atropine Eye Drops for Myopia Progression. Asia Pac J Ophthalmol (Phila). 2019;8(5):360-365.
11. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624-630.
12. Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33 (1):3-13.
13. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368.
14. Lakkis C, Weidemann K. Evaluation of the performance of photochromic spectacle lenses in children and adolescents aged 10 to 15 years. Clin Exp Optom. 2006;89(4):246-252.
15. Renzi-Hammond LM, Hammond BR Jr. The effects of photochromic lenses on visual performance. Clin Exp Optom. 2016;99(6):568-574.
16. Wu PC, Kuo HK. Effect of photochromic spectacles on visual symptoms and contrast sensitivity of myopic schoolchildren treated with low dose concentration atropine. Invest Ophthalmol Vis Sci. 2016;57:2484.
17. Vorliegende Hoya-Daten. Transmissions-, Ampelerkennungs- und UV-Blockierungstest für MiYOSMART clear und MiYOSMART Sonnenbrillengläser. 02/2023 Die Tests wurden bei Raumtemperatur (23 °C) durchgeführt.
18. Vorliegende Hoya-Daten. Linsenleistungsvalidierungstest für photochrome MiYOSMART Gläser – Aktivierung und Deaktivierung. 02/2023
19. Quintana MS, Langa A, del Moral-Martinez I, et al. Polarized Filters Enhance Contrast Sensitivity When Glare Is Produced On A Flat Surface Under Photopic Conditions. Invest Ophthalmol Vis Sci. 2006;47(13):1225.